Introduction. Chronic recurrent cystitis (CRC) is one of the most common urological diseases in women. Given the proven role of immune disorders in the development of chronic urinary tract infections (UTIs), insufficient effectiveness of antibacterial therapy, the risk of selection of resistant strains of microorganisms, the advisability of using immunomodulators is justified. The purpose of the study: to evaluate the effectiveness of the immunomodulatory drug Galavit® in the complex therapy of patients with CRC.

Materials and methods. The study involved 68 women. The main group consisted of 36 patients who, in addition to antimicrobial therapy, were prescribed a course of Galavit® in the form of intramuscular injections for recurrent cystitis. The control group consisted of 32 patients who, in case of recurrent cystitis, received only standard therapy. The results were assessed 3 and 6 months after the start of therapy based on the clinical manifestations of the disease by filling in the questionnaires of acute cystitis symptoms (ACSS), visual analog scale (VAS) for pain and laboratory data (general urine analysis, urine culture data).

Results. The inclusion of Galavit® in the complex therapy of CRC allows not only to quickly and effectively relieve the symptoms of exacerbation of the disease, but also to achieve a long and stable relapse-free period. Only 2 (5.5%) patients had a relapse of cystitis during 6 months of observation after complex therapy using Galavit®, while in the control group, clinical manifestations of relapse were registered in 13 (40.6%) patients. In addition, against the background of the use of Galavit®, the vast majority of women did not have clinically significant bacteriuria up to 6 months of observation (only 2 patients had asymptomatic bacteriuria after 6 months).

Conclusion. The use of the immunomodulatory drug Galavit® can be effective not only for the purpose of increasing the effectiveness of the course of antimicrobial therapy during the period of exacerbation of CRC, but also for the prevention of relapses after clinical improvement has been achieved.